Mer­ck dives deep­er in­to KRAS, team­ing up with Tai­ho, As­tex to de­vel­op small mol­e­cule drugs

As the race — led by Am­gen — to sub­due the no­to­ri­ous KRAS onco­gene heats up in the ear­ly clin­i­cal space, Mer­ck has de­cid­ed it’s not enough …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA